Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
2024-513435-24-01Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Neuralgia and distal sensorimotor polyneuropathy (DSPN) comparing LY3848575 with Placebo (2 arms). Primary endpoint: Mean change from baseline in Average Pain Intensity Numeric Rating Scale (API-NRS). Started May 2025; status: completed.
02
Drugs
LY3848575
03
Conditions
Neuralgiadistal sensorimotor polyneuropathy (DSPN)
Beyond the preview
Go deeper on 2024-513435-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513435-24-01.